Co-Diagnostics, Inc.·4

May 27, 4:02 PM ET

NELSON JAMES B 4

Research Summary

AI-generated summary

Updated

Co-Diagnostics Director James B. Nelson Receives RSU Award

What Happened
James B. Nelson, a director of Co-Diagnostics, Inc. (CODX), reported the acquisition of 1,695 shares (code A) and the conversion/exercise of a derivative resulting in the disposition of 1,695 shares (code M) on May 23, 2026. Both entries show a $0.00 price, consistent with restricted stock units (RSUs) vesting and converting into common shares rather than an open-market purchase or sale for cash.

Key Details

  • Transaction date: 2026-05-23; Form 4 filed 2026-05-27. Filing appears to meet the SEC two-business-day reporting requirement.
  • Reported transactions: A — 1,695 shares acquired @ $0.00; M — 1,695 shares disposed @ $0.00 (conversion of derivative).
  • No cash paid or received in these entries; this reflects RSU vesting/conversion, not a sale.
  • Shares owned after the transaction: not specified in the filing.
  • Footnote: these shares are part of previously awarded RSUs — 2,334 RSUs (awarded 6/12/2023), 3,667 RSUs (4/26/2024), and 4,167 RSUs (8/13/2025) — which vest in six equal installments every six months (vesting schedules listed in the footnote).

Context

  • The transactions look like routine RSU vesting and conversion into common stock (derivative exercise), which commonly show $0 exercise price because the shares were awarded earlier. This is not an open-market sale or purchase.
  • Such vesting events are standard compensation mechanics and do not by themselves indicate a change in insider sentiment.